AVITA Medical, Inc. (RCEL)

Market Cap	241.13M
Revenue (ttm)	51.57M
Net Income (ttm)	-35.38M
Shares Out	25.71M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,325
Open	9.81
Previous Close	9.70
Day's Range	9.34 - 9.88
52-Week Range	9.16 - 21.70
Beta	1.29
Analysts	Strong Buy
Price Target	28.25 (+201.17%)
Earnings Date	May 13, 2024

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 ...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: James M. Corbett
• Employees: 207
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL

Financial Performance

In 2023, AVITA Medical's revenue was 51.57 million, an increase of 37.03% compared to the previous year's 37.64 million. Losses were -35.38 million, 32.7% more than in 2022.

Financial numbers in AUD

Analyst Forecast

According to 5 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price forecast is $28.25, which is an increase of 201.17% from the latest price.

Price Target

$28.25

(201.17% upside)

Analyst Consensus: Strong Buy